Form 4: MAIA Director Acquires 24,060 Stock Options

MAIA Biotechnology Director Jean-Manasse Theagene was granted 24,060 stock options exercisable at $1.53 per share, vesting immediately.

Summary

• Director Jean-Manasse Theagene acquired 24,060 stock options in MAIA Biotechnology, Inc.
• The options were granted on December 31, 2025, under the company's 2021 Equity Incentive Plan.
• The exercise price for these options is $1.53 per share.
• The options vest 100% on the grant date and are immediately exercisable.
• The options have an expiration date of December 31, 2035.

Sentiment

Score: 7

Explanation: The grant of options to a director is generally a positive signal of alignment and confidence in the company's future, though it represents a routine compensation event rather than a major strategic announcement.

Positives

• A director acquiring stock options can signal confidence in the company's future performance and strategic direction.
• The immediate 100% vesting of the options provides the director with immediate equity exposure and aligns their interests with long-term shareholder value.

Future Outlook

The options have an expiration date of December 31, 2035, indicating a long-term incentive for the director to contribute to the company's sustained growth and value creation.

Industry Context

This is a standard equity compensation event for a director in a publicly traded biotechnology company, aligning management incentives with shareholder interests over the long term. Such grants are common practice to attract and retain experienced board members.

Comparison to Industry Standards

• Granting stock options to directors is a common practice in the biotechnology industry, similar to compensation structures seen in companies like Moderna or BioNTech, to incentivize long-term performance and retention.
• The immediate vesting for director grants is also a frequent occurrence, providing immediate alignment with company performance.

Stakeholder Impact

• Shareholders: Potential for increased alignment between director and shareholder interests due to equity ownership.
• Employees: No direct impact on general employees from this specific filing.
• Customers/Suppliers/Creditors: No direct impact from this specific filing.

Next Steps

• The director may choose to exercise these options at any time between the exercisable date (December 31, 2025) and the expiration date (December 31, 2035), assuming the stock price is above the exercise price of $1.53.

Key Dates

Keywords

MAIA Biotechnology, MAIA, Stock Options, Director Compensation, Equity Incentive Plan, Insider Transaction, Form 4, Beneficial Ownership